Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 235

Results For "quality"

2393 News Found

Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets
News | July 01, 2021

Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets

TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg


Lonza to expand API manufacturing facility in Nansha, China
News | June 28, 2021

Lonza to expand API manufacturing facility in Nansha, China

The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022


Glenmark receives ANDA approval for inhalation solution
News | June 24, 2021

Glenmark receives ANDA approval for inhalation solution

Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina


Vaishali Pharma bags $100,000 order from Russia
News | June 23, 2021

Vaishali Pharma bags $100,000 order from Russia

The company has predominantly built a portfolio into veterinary products


Govt. to increase Janaushadhi Kendras to 10,000
News | June 15, 2021

Govt. to increase Janaushadhi Kendras to 10,000

Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country


Lupin receives warning letter from U.S. FDA
News | June 14, 2021

Lupin receives warning letter from U.S. FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility


Alkem launches Perampil tablets at affordable prices
News | June 11, 2021

Alkem launches Perampil tablets at affordable prices

The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:


Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
News | June 02, 2021

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.


Lasa Supergenerics FY21 profit up 521%
News | June 02, 2021

Lasa Supergenerics FY21 profit up 521%

Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%